Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological Response Modifiers Programme and cancer chemotherapy.

R K Oldham

    International Journal of Tissue Reactions
    |January 1, 1982
    PubMed
    Summary

    The National Cancer Institute

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Growth of tumor-derived activated T cells for the treatment of advanced cancer.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    "Historical Vignettes".

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Cancer biotherapy: when, why and how long?

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Fundamentally different.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Treatment of drug resistance: biotherapy or chemotherapy?

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer.

    Cancer biotherapy & radiopharmaceuticals·2000

    Area of Science:

    • Oncology
    • Immunology
    • Pharmacology

    Background:

    • The National Cancer Institute's Biological Response Modifiers Programme (BRMP) evaluates biological substances for cancer treatment.
    • Potential biological response modifiers (BRM) include immunomodulators, interferons, cytokines, and antibodies.

    Purpose of the Study:

    • To assess the therapeutic potential of biological response modifiers (BRM) in cancer treatment.
    • To evaluate BRM efficacy in preclinical models as a prerequisite for clinical trials.

    Main Methods:

    • Preclinical evaluation of novel agents as potential BRM.
    • Testing BRM for their ability to alter biological responses, including toxic and therapeutic effects.
    • Investigating the predictive value of optimizing BRM activity for therapeutic efficacy.

    Main Results:

    • Preliminary results with interferon, thymic factors, and immune modulators are promising but require further investigation.
    • Ongoing research focuses on purified cytokines, tumor-associated antigens, and monoclonal antibodies for cancer therapy.

    Conclusions:

    • BRM show potential in cancer treatment, with ongoing research exploring various agents and their mechanisms.
    • Further investigation into the interaction between BRM and chemotherapy is warranted, particularly for cytokines that enhance bone-marrow-stem cell function.

    Related Experiment Videos